MLTX - CIK 0001821586
The table below shows MoonLake Immunotherapeutics's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $54.52M | $60.63M | $49.76M | $36.46M | $35.74M | $23.66M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.51M |
| $10.80M |
| $10.94M |
| $11.03M |
| $7.38M |
| $6.92M |
| Operating income | -$70.02M | -$71.43M | -$60.70M | -$47.48M | -$43.11M | -$30.58M |
| Income tax | $622.00K | $115.00K | $95.00K | $153.00K | $92.00K | $79.00K |
| Net income | -$69.71M | -$69.73M | -$55.22M | -$39.94M | -$35.39M | -$24.27M |
| EPS (diluted) | -$0.98 | -$1.10 | -$0.87 | -$0.63 | -$0.56 | -$0.39 |